Compare RNR & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNR | FMS |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | Bermuda | Germany |
| Employees | 1040 | 109698 |
| Industry | Property-Casualty Insurers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.5B |
| IPO Year | N/A | N/A |
| Metric | RNR | FMS |
|---|---|---|
| Price | $300.53 | $22.59 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 14 | 2 |
| Target Price | ★ $322.31 | $30.00 |
| AVG Volume (30 Days) | 256.9K | ★ 451.4K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | 0.53% | ★ 2.57% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.19 | $3.83 |
| P/E Ratio | ★ $5.42 | $15.62 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $231.17 | $20.96 |
| 52 Week High | $318.20 | $30.46 |
| Indicator | RNR | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 45.51 |
| Support Level | $288.11 | $22.50 |
| Resistance Level | $305.73 | $24.02 |
| Average True Range (ATR) | 7.32 | 0.36 |
| MACD | -1.47 | -0.07 |
| Stochastic Oscillator | 34.79 | 25.08 |
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.